> To determine whether this reflects a common effect of psilocybin that generalizes across datasets and psychedelics, we calculated dimension 1 scores for extant datasets from participants receiving intravenous (i.v.) psilocybin55 and lysergic acid diethylamide (LSD)56. Psychedelic treatment increased dimension 1 in nearly every participant in the psilocybin and LSD datasets (Fig. 2c), suggesting that this is a common effect across psychedelic drugs and individuals.